
AbbVie files continuous Parkinson’s therapy ABBV-951 in US
AbbVie has filed for approval of its therapy for Parkinson’s disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current […]
AbbVie has filed for approval of its therapy for Parkinson’s disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current […]
AbbVie has reported that a subcutaneous infusion of Parkinson’s disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving […]
Shots: The P-III M15-736 Study evaluates the efficacy, safety & tolerability of ABBV-951 to levodopa/carbidopa in 130 adult patients with advanced PD across 80 sites […]
Copyright © 2022 | WordPress Theme by MH Themes